HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sweet, B. V. Search for Related Content PubMed PubMed Citation Articles by Sweet, B. V.

BURGUNDA V. SWEET, PHARM.D., is Clinical Associate Professor of Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, and Director, Drug Information and Investigational Drug Services, University of Michigan Hospitals and Health Centers, Ann Arbor.

Address correspondence to Mary Ellen Bonk, Pharm.D., University HealthSystem Consortium, 2001 Spring Road, Suite 700, Oak Brook, IL 60523-1890 (bonk{at}uhc.edu).

Purpose. The pharmacology, pharmacokinetics, indications, clinical efficacy, adverse effects, drug interactions, and dosage and administration of natalizumab are reviewed. Summary. Natalizumab, the first commercially available selective adhesion-molecule inhibitor, is approved as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis (MS). Natalizumab exerts its immunologic effects by targeting the 4 integrin receptor, the site responsible for the migration of leukocytes from the blood into inflamed tissues. Because of the increased risk of progressive multifocal leukoencephalopathy (PML), natalizumab is generally recommended for patients who have had an inadequate response to or are intolerant of alternative MS therapies. Data evaluating the efficacy and safety of natalizumab for the treatment of MS are available from published Phase II and III trials. The most common adverse effects reported include headache, fatigue, urinary-tract infection, depression, arthralgia, and lower respiratory-tract infection. The recommended dosage of natalizumab for the treatment of relapsing forms of MS is 300 mg administered by i.v. infusion over one hour once every four weeks. Natalizumab is available only through a risk-minimization program run by the manufacturer. Conclusion. Natalizumab offers an effective treatment option for patients with MS who have had an inadequate response to or are intolerant of alternative MS therapies. Because of its potential to increase the risk of PML, the risks and benefits should be carefully weighed before initiating natalizumab therapy in patients with MS. Natalizumab should not be used to treat Crohn’s disease or any other unapproved indication until more postmarketing safety data are available. Index terms: Antibodies; Dosage; Drug administration; Drug interactions; Mechanism of action; Multiple sclerosis; Natalizumab; Pharmacokinetics; Risk management; Toxicity

 

This article has been cited by other articles:

				H. Ilanjian and R. Shane Washout period for immune-modifying drugs before natalizumab therapy Am. J. Health Syst. Pharm., January 1, 2008; 65(1): 18 - 19. [Full Text] [PDF]